Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the Annals of Internal Medicine has published additional data from the Phase 3 MOVe-OUT trial evaluating LAGEVRIO™ (molnupiravir), an investigational oral antiviral medicine, in non-hospitalized adults with mild to moderate COVID-19 who were at high risk for progressing to severe disease.
- Read more about Merck Announces molnupiravir data which required less Acute Care Visit
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/merck-announces-molnupiravir-data-which-required-less-acute-care-visit
No comments:
Post a Comment